{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:09:45Z","timestamp":1775480985434,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"DOI":"10.7759\/cureus.106517","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:34:28Z","timestamp":1775478868000},"source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic Stewardship: Comparing Meropenem De-Escalation and Continued Therapy When Cultures Show No Multi-Drug Resistance"],"prefix":"10.7759","author":[{"given":"Sean","family":"Swieczkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan A","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwina E","family":"Brathwaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Y","family":"McCue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricar","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Centers for Disease Control and Prevention. Core elements of antibiotic stewardship. (2025). Accessed: April 6, 2026: https:\/\/www.cdc.gov\/antibiotic-use\/hcp\/core-elements\/index.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050467","article-title":"Antibiotic de-escalation in the intensive care unit: rationale and potential strategies","volume":"14","author":"Matuszak SS","year":"2025","unstructured":"Matuszak SS, Kolodziej L, Micek S, Kollef M. Antibiotic de-escalation in the intensive care unit: rationale and potential strategies. Antibiotics (Basel). 2025, 14:10.3390\/antibiotics14050467","journal-title":"Antibiotics (Basel)"},{"key":"ref3","article-title":"Update on the adverse effects of antimicrobial therapies in community practice","author":"Mohsen S","year":"2020","unstructured":"Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice. Can Fam Phys. 2020, 651-659.","journal-title":"Can Fam Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas KZ","year":"2012","unstructured":"Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012, 67:2793-803. 10.1093\/jac\/dks301","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris PN","year":"2018","unstructured":"Harris PN, Tambyah PA, Lye DC, et al.. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018, 320:984-94. 10.1001\/jama.2018.12163","journal-title":"JAMA"},{"key":"ref6","unstructured":"UpToDate Lexi-Drugs. Homepage. (2026). Accessed: April 6, 2026: https:\/\/online.lexi.com\/lco\/action\/login."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.11.006","article-title":"Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: a patient-level analysis of published data","volume":"55","author":"O'Donnell JN","year":"2020","unstructured":"O'Donnell JN, Rhodes NJ, Biehle LR, et al.. Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: a patient-level analysis of published data. Int J Antimicrob Agents. 2020, 55:105849. 10.1016\/j.ijantimicag.2019.11.006","journal-title":"Int J Antimicrob Agents"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"73","author":"Son SK","year":"2018","unstructured":"Son SK, Lee NR, Ko JH, et al.. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2018, 73:2631-42. 10.1093\/jac\/dky168","journal-title":"J Antimicrob Chemother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma PD","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, et al.. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024, 10.1093\/cid\/ciae403","journal-title":"Clin Infect Dis"},{"key":"ref10","unstructured":"Society of Critical Care Medicine. Navigating infections in critical care: evidence-based approaches to antimicrobial use. (2024). Accessed: April 6, 2026: https:\/\/www.sccm.org\/education-center\/educational-programming\/navigating-infections-in-critical-care."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy11030104","article-title":"Antibiotic de-escalation in critically ill patients with negative clinical cultures","volume":"11","author":"Roper S","year":"2023","unstructured":"Roper S, Wingler MJ, Cretella DA. Antibiotic de-escalation in critically ill patients with negative clinical cultures. Pharmacy (Basel). 2023, 11:10.3390\/pharmacy11030104","journal-title":"Pharmacy (Basel)"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.21315\/mjms2024.31.1.7","article-title":"Predictors of treatment failure and mortality among patients with septic shock treated with meropenem in the intensive care unit","volume":"31","author":"Mazlan MZ","year":"2024","unstructured":"Mazlan MZ, Ghazali AG, Omar M, et al.. Predictors of treatment failure and mortality among patients with septic shock treated with meropenem in the intensive care unit. Malays J Med Sci. 2024, 31:76-90.","journal-title":"Malays J Med Sci"},{"key":"ref13","unstructured":"IDSA. ATS\/IDSA guidelines for diagnosis and treatment of adults with community-acquired pneumonia. (2019). Accessed: April 6, 2026: https:\/\/www.idsociety.org\/practice-guideline\/community-acquired-pneumonia-cap-in-adults\/."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil AC","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al.. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016, 63:e61-e111. 10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05866-w","article-title":"Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)","volume":"46","author":"Tabah A","year":"2020","unstructured":"Tabah A, Bassetti M, Kollef MH, et al.. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med. 2020, 46:245-65. 10.1007\/s00134-019-05866-w","journal-title":"Intensive Care Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449647-antibiotic-stewardship-comparing-meropenem-de-escalation-and-continued-therapy-when-cultures-show-no-multi-drug-resistance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:34:30Z","timestamp":1775478870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449647-antibiotic-stewardship-comparing-meropenem-de-escalation-and-continued-therapy-when-cultures-show-no-multi-drug-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.106517","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}